Recent research using CRC cell line models revealed that atorvastatin and rosuvastatin directly target this pathway: these statins selectively downregulated PAR-2 expression and markedly reduced TNF-α secretion from CRC cells, while also suppressing aberrant calcium signaling linked to PAR-2 activation [34]. The gene discussed is F2RL1; the disease is colorectal carcinoma.